Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Eastern Kentucky University currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, reflecting a diversified approach to its current patent filings. This distribution ensures that the university's intellectual property is being reviewed by multiple specialized groups within the patent office rather than a single administrative unit. By engaging with 2 distinct art units, the university can pursue different technical aspects of its pharmaceutical research simultaneously.
The busiest examiner for the portfolio is AFREMOVA, VERA, who is responsible for 1 pending office action. Given that there are 2 distinct examiners for the 2 pending office actions, the workload is split evenly. This structure suggests that the university's prosecution outcomes are not tied to a single examiner's review style, but rather depend on the standards of 2 separate art units. Practitioners should monitor the specific requirements of both distinct examiners to maintain progress across the portfolio. Tailoring responses to the individual tendencies of each examiner will be necessary to optimize the chances of allowance for both pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17820452 | METHOD FOR DETECTION OF ESCHERICHIA COLI AND ANTIBIOTIC RESISTANT BACTERIA IN WATER | AFREMOVA, VERA | 19d overdue |
| 17792571 | RADIONUCLIDE-LHRH CONJUGATES FOR DIAGNOSIS OF REPRODUCTIVE CANCERS | DONOHUE, SEAN R | 8d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17820452 | METHOD FOR DETECTION OF ESCHERICHIA COLI AND ANTIBIOTIC RESISTANT BACTERIA IN WATER | AFREMOVA, VERA | 19d overdue |
| 17792571 | RADIONUCLIDE-LHRH CONJUGATES FOR DIAGNOSIS OF REPRODUCTIVE CANCERS | DONOHUE, SEAN R | 8d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17820452 | METHOD FOR DETECTION OF ESCHERICHIA COLI AND ANTIBIOTIC RESISTANT BACTERIA IN WATER | AFREMOVA, VERA | 1653 | §103§112 | Final Rejection | 19d overdue | Pending | Aug 17, 2022 |
| 17792571 | RADIONUCLIDE-LHRH CONJUGATES FOR DIAGNOSIS OF REPRODUCTIVE CANCERS | DONOHUE, SEAN R | 1618 | §103§112Other | Final Rejection | 8d | Pending | Jul 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial